A few days ago, the Changchun Changsheng problem vaccine incident broke out, and a stone provoked a thousand layers of waves. The voice of criticism from the whole country was endless. Some people are profit-seeking, and some people are worried about the people's livelihood and social responsibility. They should shoulder the social responsibilities of business people.
It can be seen that artificial intelligence technology has been hot in recent years, state support, capital boost, and entrepreneurs have bet on this track. Even if there is a bubble, it is undeniable that this wave has brought tangible value to society. Taking medical care as an example, whether it is medical imaging before treatment, virtual assistants, assisted diagnosis during treatment, intelligent consultation, drug research and development, or health management for rehabilitation, all startups use emerging technologies. Improve the performance of China's medical resources. As one entrepreneur said: "Since China's medical resources are not enough, then we must use AI to complete some of the most basic work."
The entrepreneur, Chen Hui, founder and CEO of Yasen Technology, a medical artificial intelligence company interviewed by Yiou, introduced to Yiou: "We can't just regard it as an appeal to AI. A tool for reading a film, first of all we have to look at what is really missing in the Chinese market."
Before you leave, think about what is missing in China's medical care.
What is missing in China's medical care?
From a social perspective, the lack of medical resources; from the enterprise level, the lack of specialist AI.
"Artificial Intelligence + Medical" must first solve the problem of helping hospital departments to improve the level of clinical technology, especially for second- and third-tier cities where the specialist resources are relatively weak, how to reduce the ability of specialist AI to clinically assisted diagnosis to primary hospitals. Instead of just sinking a reading software, this is a core issue that Yasen has been thinking about for years.
The first thing that needs to be solved is how to make a decent product in the specialist AI?
At the diagnostic level, Yasen Technology hopes that its products can simulate doctors' diagnostic behavior as much as possible. The doctor will make a definitive diagnosis based on the patient's clinical information, biochemical data, and a variety of imaging data, according to the clinical path to complete the collection and analysis of all data. For Yasen, how to make a report on assisted diagnosis at this level is the focus of attention at this stage.
According to Chen Hui, clinical multi-dimensional diagnosis is highly complex, and it needs to have good analytical ability for data of at least 3-4 dimensions, and it is necessary to give different weights to each data in order to support clinical decision support. This requires the company not only to have the accumulation of deep learning, bioengineering algorithms, but also the medical knowledge, clinical experience, and integrated learning capabilities of deep learning + machine learning.
The second thing to face is the problem of sinking medical resources.
From the introduction of Chen Hui, billions of Europeans have learned that China's hardware resources have made great progress in the past decade. The imaging equipment used by second- and third-tier city hospitals does not have any quality problems.
The real headache is the quality of the diagnosis. As we all know, the amount of outpatients in China is huge, and in this case there is no guarantee that every operation of the doctor is accurate. Therefore, when sinking, Yasen Technology not only helps hospitals in second- and third-tier cities to achieve technological innovation, but also helps hospitals in quality control in commercial operations and medical operations. Chen Hui said: "This is a challenge and a must for companies in the medical industry ."
The first is to change the doctor's concept: for example, if you want to find stroke through nuclear magnetic, patients usually need to perform a 2-3 mm layer of nuclear magnetic scan, but in a large number of local hospitals, because the outpatient volume is too large, doctors usually Only images with a layer thickness of 7-8 mm will be referenced. But this will also miss a lot of tiny bleeding points. In order to improve the amount of reception and not to reduce the quality of diagnosis, Yasen Technology and the hospital have negotiated to achieve maximum quality control.
The second is to help the hospital to carry out refined operations: in many primary hospitals, there are a lot of resources idle or the equipment is not fully loaded. For example, some inspections can be completed in primary hospitals or medical examination centers. Some diseases can be in secondary hospitals or top three. The hospital performs diagnosis and adjuvant treatment. Therefore, Yasen Technology hopes to help the hospital to share the workload and maximize the value of medical equipment through refined operations.
Dare to choose different, buried in multimodal brain analysis and cytopathology
It can be seen that Yasen Technology is strategically arranged through clinical multi-dimensional diagnosis and sinking the second and third tier cities. What is the thinking of Yasen at the product level? At present, most of the medical imaging companies use lung detection as an entry point. Why does Yasen choose another path rooted in the field of cranial nerves?
First of all, the brain market itself is a blue ocean and will continue to expand in the future. China has gradually entered an aging society. By 2020, the number of elderly people over the age of 60 will reach 248 million, accounting for about 17% of China's total population. Judging from past experience, when you are over 45 years old, you will enter the high incidence of encephalopathy. Moreover, with the increase of social pressure and the lack of good living habits, the health level of young people is gradually declining, and the age of onset of brain diseases is showing a younger trend. Based on the above phenomenon, Chen Hui believes that in the next decade, China's encephalopathy will enter a period of high incidence. Better service to China's aging society is of great strategic importance both in terms of business value and social significance.
Second, complex brain image processing technology has become a unique threshold for Yasen technology. A large number of tumor-like diseases, including pulmonary nodules, are highly dependent on CT, and CT imaging examinations that reflect changes in tissue density are effective. However, this situation does not apply to brain diseases. In addition to brain tumors, a large number of neurodegenerative diseases do not have solid tumors in the brain. The range of CT imaging applications is greatly reduced compared to other organs.
Functional images play an important role in brain examination, namely fMRI, PET and so on. These images have brought great obstacles to the research of products of various companies. Most companies doing CT image analysis do not have a strong biomedical engineering background, and it is difficult to analyze from the complexities of the original product to the brain image.
Chen Hui said: "I predict that there will be two phenomena in the future of medical imaging companies. One is that some companies will continue to expand horizontally based on CT images, covering products to different organs such as lungs and gastrointestinal tract; Some companies will plow in the vertical field and conduct a complete analysis of the data in the vertical direction for a disease or organ, namely the specialist AI proposed by Yasen."
Yasen Technology has the ability to analyze different kinds of biomedical images such as nuclear magnetic, PET, SPECT, and brain electricity in the brain. It can capture characteristics from different data and complete Alzheimer's disease, epilepsy, and Parkinson's disease. Multidimensional analysis of specific encephalopathy. At present, Yasen Technology has cooperated with some medical institutions and private hospitals for artificial intelligence products of Alzheimer's disease.
As Chen Hui said, the incidence of Alzheimer's disease has reached more than 10% in the 65-year-old population. In this case, early detection and effective treatment become the most effective way to delay the disease. The living standards of the elderly and the pressure to reduce the old age of the young people have far-reaching significance.
Yasen Technology has two product lines, one of which is the above-mentioned multi-modal brain analysis product, and the other is the product that can be clearly commercialized - cell pathology.
Cytopathology is a subdivision of pathology and has a wide range of applications in the laboratory. For example, blood routine testing, although most hospitals can use automatic blood analysis, biochemical methods to check, but still some blood routines can not get good indicators under the automatic analyzer, which requires relying on manual microscopy Screening.
Chen Hui introduced to Yiou: "The principle of this cell cytopathology is not complicated, but its application scenario is very rich, and it has a great practical effect on the clinic." Chen Hui believes that artificial intelligence will first land and produce in the pathology. Business income.
Not only the reading tool, AI can empower the upstream and downstream of the medical industry chain.
What is the value of a medical artificial intelligence company? Is it possible to make tools that help radiologists read the film, or can they play other roles?
As Chen Hui's point of view quoted at the beginning of this article: "Our appeal to AI can't just be seen as a tool for reading."
From the perspective of patients and hospitals, the appeal of artificial intelligence in this group of people is to find the disease as soon as possible and to be cured. Taking lung cancer as an example, the survival rate of lung cancer patients in China is much lower than that of the United States and Japan. The reason is that some countries in foreign countries have strong early detection ability for potential patients. In our country, especially in rural areas and grassroots areas, patients can only go to the hospital if they show very serious symptoms. At this time, they often reach the middle and late stage of cancer and miss the best time for treatment. The reason is that China lacks sufficient medical resources to sink, and the use of AI technology can copy the doctor's experience to every village and town. This is precisely the most effective way to solve the resource shortage problem.
After artificial intelligence has unearthed the patient, if it is in the early stage, it can support the pharmaceutical company to develop an early treatment for the patient. More importantly, the large patient database built by artificial intelligence can help the drug factory to test in the fourth clinical stage after the drug is marketed. To put it simply, artificial intelligence will help pharmaceutical companies to understand the attributes of patients, better understand the real world, and make the most accurate judgments to improve the drug development process.
For device manufacturers, if artificial intelligence technology can tap enough patients with encephalopathy, it can provide more development ideas for device manufacturers. For example, if epilepsy can provide early warning 5 minutes before the onset of epilepsy, device manufacturers can develop relevant portable EEG devices or ECG devices to monitor early epileptic patients to reduce the frequency of accidents.
In general, artificial intelligence-enhanced medical imaging can not only help patients with early screening and refined auxiliary diagnosis, but also establish a large database of patients during the treatment process to help drug development, device development and doctor resources in the later industrial chain. to cultivate. Artificial intelligence will definitely connect a large number of doctor resources, pharmaceutical companies and even clinics.
At the end of the interview, Chen Hui told Yiou, Yasen is building a database of diseases for brain diseases to better serve patients, pharmaceutical companies and device manufacturers. In the next two years, Yasen Technology will enter the medical examination institutions and private hospitals on a large scale around the brain products of the central nervous system. “Yason’s products will never stay at the laboratory level, and it will definitely be closer to reality.â€
Infection Control Equipment,Dental Root Canal,Teeth Cleaning Equipment,Dental Suction Unit
Foshan Ja Suo Medical Device Co., LTD , https://www.jasuodental.com